Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of ertugliflozin in pediatric type 2 diabetes
MOH_2019-10-06_007265Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Ertugliflozin add-on with Placebo add-on (2 arms). Primary endpoint: Primary endpoint not reported. Started Jul 2019; status: active, not recruiting.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2019-10-06_007265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-10-06_007265.